...
search icon
crl-img

Charles River Laboratories, Common Stock

CRL

NYQ

$163.12

+$1.5

(0.93%)

1D
Industry: Life Sciences Tools & Services Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$8.26B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
20.1773
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.46M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.38
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$159.65 L
$275 H
$163.12

About Charles River Laboratories, Common Stock

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts. more

Industry: Life Sciences Tools & ServicesSector: Health Care

Returns

Time FrameCRLSectorS&P500
1-Week Return-0.32%0.63%-1.11%
1-Month Return-13.94%6.06%0.39%
3-Month Return-10.61%0.46%4.94%
6-Month Return-27.95%0.42%15.68%
1-Year Return-25.03%3.52%21.45%
3-Year Return-51.4%11.44%33.25%
5-Year Return4.06%44.83%81.76%
10-Year Return136.17%112.91%193.72%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue2.62B2.92B3.54B3.98B4.13B[{"date":"2019-12-31","value":63.48,"profit":true},{"date":"2020-12-31","value":70.81,"profit":true},{"date":"2021-12-31","value":85.73,"profit":true},{"date":"2022-12-31","value":96.29,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue1.66B1.85B2.21B2.51B2.63B[{"date":"2019-12-31","value":63.3,"profit":true},{"date":"2020-12-31","value":70.44,"profit":true},{"date":"2021-12-31","value":83.96,"profit":true},{"date":"2022-12-31","value":95.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit958.31M1.07B1.33B1.46B1.50B[{"date":"2019-12-31","value":63.78,"profit":true},{"date":"2020-12-31","value":71.45,"profit":true},{"date":"2021-12-31","value":88.82,"profit":true},{"date":"2022-12-31","value":97.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin36.56%36.72%37.70%36.79%36.39%[{"date":"2019-12-31","value":96.98,"profit":true},{"date":"2020-12-31","value":97.39,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.58,"profit":true},{"date":"2023-12-31","value":96.52,"profit":true}]
Operating Expenses607.16M640.81M744.78M811.68M816.39M[{"date":"2019-12-31","value":74.37,"profit":true},{"date":"2020-12-31","value":78.49,"profit":true},{"date":"2021-12-31","value":91.23,"profit":true},{"date":"2022-12-31","value":99.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income351.15M432.73M589.86M650.98M617.26M[{"date":"2019-12-31","value":53.94,"profit":true},{"date":"2020-12-31","value":66.47,"profit":true},{"date":"2021-12-31","value":90.61,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.82,"profit":true}]
Total Non-Operating Income/Expense(106.43M)(71.21M)(182.41M)(86.50M)(169.97M)[{"date":"2019-12-31","value":-10642700000,"profit":false},{"date":"2020-12-31","value":-7121400000,"profit":false},{"date":"2021-12-31","value":-18241000000,"profit":false},{"date":"2022-12-31","value":-8649900000,"profit":false},{"date":"2023-12-31","value":-16997400000,"profit":false}]
Pre-Tax Income304.08M447.11M480.71M622.99M581.28M[{"date":"2019-12-31","value":48.81,"profit":true},{"date":"2020-12-31","value":71.77,"profit":true},{"date":"2021-12-31","value":77.16,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.31,"profit":true}]
Income Taxes50.02M81.81M81.87M130.38M100.91M[{"date":"2019-12-31","value":38.37,"profit":true},{"date":"2020-12-31","value":62.75,"profit":true},{"date":"2021-12-31","value":62.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":77.4,"profit":true}]
Income After Taxes254.06M365.31M398.84M492.61M480.37M[{"date":"2019-12-31","value":51.57,"profit":true},{"date":"2020-12-31","value":74.16,"profit":true},{"date":"2021-12-31","value":80.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.52,"profit":true}]
Income From Continuous Operations254.06M365.31M398.84M492.61M480.52M[{"date":"2019-12-31","value":51.57,"profit":true},{"date":"2020-12-31","value":74.16,"profit":true},{"date":"2021-12-31","value":80.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.55,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income252.02M364.30M390.98M486.23M474.62M[{"date":"2019-12-31","value":51.83,"profit":true},{"date":"2020-12-31","value":74.92,"profit":true},{"date":"2021-12-31","value":80.41,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.61,"profit":true}]
EPS (Diluted)6.738.1410.3311.1310.65[{"date":"2019-12-31","value":60.47,"profit":true},{"date":"2020-12-31","value":73.14,"profit":true},{"date":"2021-12-31","value":92.81,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.69,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CRL
Cash Ratio 0.21
Current Ratio 1.48
Quick Ratio 1.14

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CRL
ROA (LTM) 4.87%
ROE (LTM) 11.92%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CRL
Debt Ratio Lower is generally better. Negative is bad. 0.52
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.47

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CRL
Trailing PE 20.16
Forward PE 17.15
P/S (TTM) 2.05
P/B 2.19
Price/FCF 39
EV/R 2.66
EV/Ebitda 10.92
PEG 2.24

FAQs

What is Charles River Laboratories share price today?

Charles River Laboratories (CRL) share price today is $163.12

Can Indians buy Charles River Laboratories shares?

Yes, Indians can buy shares of Charles River Laboratories (CRL) on Vested. To buy Charles River Laboratories from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRL stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Charles River Laboratories be purchased?

Yes, you can purchase fractional shares of Charles River Laboratories (CRL) via the Vested app. You can start investing in Charles River Laboratories (CRL) with a minimum investment of $1.

How to invest in Charles River Laboratories shares from India?

You can invest in shares of Charles River Laboratories (CRL) via Vested in three simple steps:

  • Click on Sign Up or Invest in CRL stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Charles River Laboratories shares
What is Charles River Laboratories 52-week high and low stock price?

The 52-week high price of Charles River Laboratories (CRL) is $275. The 52-week low price of Charles River Laboratories (CRL) is $159.65.

What is Charles River Laboratories price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Charles River Laboratories (CRL) is 20.1773

What is Charles River Laboratories price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Charles River Laboratories (CRL) is 2.19

What is the Market Cap of Charles River Laboratories?

The market capitalization of Charles River Laboratories (CRL) is $8.26B

What is Charles River Laboratories’s stock symbol?

The stock symbol (or ticker) of Charles River Laboratories is CRL

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top